Baseline PSA Screening and Long-Term Prostate Cancer Risk

​Baseline levels of prostate-specific antigen (PSA) at age 55 to 60 are correlated with men's long-term risk of developing clinically significant prostate cancer, according to a secondary analysis of long-term follow-up results from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.Once broadly accepted as a tool for the early detection of prostate cancer, PSA screening has become controversial in recent years due to issues of overdiagnosis and overtreatment of slow-growi...
Continue reading

Progress in Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

Last week, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, spoke with i3 Health about the recent approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. In this second installment, Dr. Armstrong discusses the ongoing evolution of therapeutic strategies in mCSPC and shares his advice fo...
Continue reading

Avapritinib Approved: Gastrointestinal Stromal Tumor With PDGFRA Exon 18 Mutation

​The FDA has approved avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) with platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, including D842V mutations, the most common type of exon 18 mutation. Up to 10% of patients with GIST harbor PDGFRA mutations, which have been linked to GIST development."GIST harboring a PDGFRA exon 18 mutation do not respond to standard therapies for GIST," commented Rich...
Continue reading

Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

​The FDA recently added a new approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer, based on data from the ARCHES and ENZAMET trials. In this interview with i3 Health, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, discusses the approval's significance and compares the variety of options that are now available for the treatment of metastatic hormone-sensitive disease.What are the greatest challen...
Continue reading

Genital Powder and Ovarian Cancer Risk: No Significant Link

​In recent years, a number of lawsuits have highlighted concerns regarding a possible link between ovarian cancer risk and the use of talc-containing cosmetic powders in the genital area. However, a large pooled analysis now published in JAMA reports no statistically significant association between genital powder use and ovarian cancer.The potential connection between genital powder use and ovarian cancer risk was first investigated because of the relationship between talcum powder and asbestos,...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.